

New Law Establishes Purple Book Patent Disclosure Requirement

January 21, 2021

Signed into law on December 27, 2020, the Biological Product Patent Transparency Act (42 U.S.C. § 262(k)(9)) requires biological reference product sponsors to provide to the US Food and Drug Administration within 30 days of disclosure the patent lists that they serve on biosimilar applicants pursuant to sections (l)(3)(A) or (l)(7) of the Biologics Price Competition and Innovation Act (BPCIA). The expiry date for each listed patent also must be provided. Disclosed patents will be made publicly available in the Purple Book beginning in June 2021.

The act is a step toward the Orange Book model, which requires identification of covered patents that may be asserted in an Abbreviated New Drug Application. The act therefore may provide efficiencies for some biosimilar applicants:

1. The new disclosure requirements will have no impact on a first biosimilar applicant for a given product. That first applicant will, as before, enter the pre-litigation patent list exchange armed only with information gleaned from its own diligence.
2. For second or later biosimilar applicants, the disclosures somewhat reduce the risk that the patent dance results in the surprise identification of patent rights about which the biosimilar applicant was unaware.
3. The Purple Book's patent lists will be most informative about patents that are difficult to uncover in a freedom-to-operate analysis, such as patents that have been exclusively licensed or that cover manufacturing processes, platform technologies, cell lines or ingredients used in manufacturing.
4. Over time, these Purple Book disclosures may also inform biosimilar program development and launch strategies across biosimilar products where manufacturing processes, inputs or platform technologies overlap.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our [legal notices](#).

Key Contacts

Orion Armon Colorado	oarmon@cooley.com +1 720 566 4119
Jonathan Davies Washington, DC	jdavies@cooley.com +1 202 776 2049
Daniel Knauss Palo Alto	dknauss@cooley.com +1 650 843 5287
Dr. Michelle Rhyu Palo Alto	rhyums@cooley.com +1 650 843 5505
Sanya Sukduang Washington, DC	ssukduang@cooley.com +1 202 776 2982

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.